Trump Administration Plans 100% Tariffs on Pharmaceutical Imports

The Trump administration is moving forward with plans to impose tariffs as high as 100% on pharmaceutical imports, according to a Financial Times report citing sources familiar with the matter. The levies could be announced as early as Thursday and would apply specifically to drug manufacturers that have not reached agreements with the White House.

This latest trade policy move follows through on threats President Trump made late last year, when he warned pharmaceutical companies that steep import duties would be imposed on branded and patented medications unless manufacturers committed to building production facilities on American soil. The administration's approach creates a clear incentive structure: companies that negotiate deals with the White House would face capped tariff rates, while those that do not comply could bear the full 100% levy.

Several major pharmaceutical giants have already moved to align themselves with the administration's demands. Pfizer, AstraZeneca, and Novo Nordisk are among the global drug makers that have signed agreements with the White House, positioning themselves to avoid the harshest penalties under the new policy.

The pharmaceutical tariff push is consistent with Trump's broader economic agenda, which centers on reshoring American manufacturing and reducing the country's dependence on foreign-made goods. By targeting the pharmaceutical sector, the administration aims to bring drug production back to the United States, a goal that gained renewed urgency following supply chain disruptions exposed during the COVID-19 pandemic.

The announcement is expected to send ripples through global pharmaceutical markets, raising concerns among investors, healthcare providers, and consumers about the potential impact on drug pricing and supply availability. Analysts warn that higher import costs could ultimately be passed on to patients, adding another layer of complexity to an already strained U.S. healthcare system. The full scope of the tariffs and their long-term economic effects remain to be seen.